DanCann Pharma’s IPO of units was oversubscribed
The subscription period for DanCann Pharma A/S’ ("DanCann Pharma" or the “Company”) IPO of units (shares and warrants) ended on October 23rd, 2020. The IPO of units was subscribed to a total of approximately DKK 55 million, corresponding to a subscription ratio of approximately 183 percent. The public part of the IPO of units was subscribed to a total of approximately 433 percent, and DanCann Pharma will thereby be provided approximately DKK 30 million (before issue costs) through the IPO of units. Through the issue of units, DanCann receives 1 644 new shareholders. Settlement notes are scheduled to be sent out today, October 28th, 2020. Corpura Fondkommission AB is the financial advisor in connection with the capitalization and listing.
DanCann Pharma’s CEO Jeppe Krog Rasmussen comments
“I would like to start by thanking everyone who has shown interest in DanCann Pharma by participating in the Company's IPO. We are very pleased with the result of the capital raising and are now looking forward to driving the Company forward using the funds raised to help patients in need of alternative treatment.
An exciting future awaits us, both as an employee, stakeholder, and shareholder - and on behalf of the Company, I look forward to the future communication in terms of the Company's many exciting upcoming milestones and achievements.”
Subscription and allocation
The IPO of units was subscribed to a total of approximately DKK 55 million, corresponding to a subscription ratio of approximately 183 percent. The public part of the IPO of units was subscribed to a total of approximately 433 percent. 6 670 000 shares and 2 668 000 warrants of series TO 1 will be issued through the IPO of units. DanCann Pharma will thereby be provided a total of approximately DKK 30 million before the total issue costs, which are estimated to amount to approximately DKK 3,8 million. The allocation of units has been decided by the Board of Directors in accordance with the principles stated in the terms in the prospectus. Settlement notes are expected to be sent out today, October 28th, 2020. Subscribers who are not allocated any units will not receive a settlement note.
Warrants of series TO 1
The exercise period for the warrants of series TO 1 issued in connection with the IPO of units have an exercise period which takes place from September 1st, 2021 until September 17th, 2021. For each warrant, the warrant holder has the right to subscribe for one new share at a price of DKK 6 per new share. If all warrants of series TO 1 are exercised, the company will be provided an additional approximately DKK 16 million before issue costs.
The number of shares and share capital
When DanCann Pharma’s IPO of units (shares and warrants) have been registered with the Danish Business Authority, the total number of shares will amount to 20 730 800 shares and the share capital amount to DKK 777 405. The total number of outstanding warrants of series TO 1 in the Company will amount to 2 668 000.
Listing at Spotlight Stock Market
DanCann Pharma’s shares and warrants are planned to be listed on Spotlight Stock Market. The first day of trading is scheduled for November 12, 2020. The shares will be traded under the ticker name "DANCAN", with ISIN code DK0061410487 and the warrants will be traded under the ticker name "DANCAN TO 1", with ISIN code DK0061410560.
Financial advisor and legal advisor and issuing agent
Corpura Fondkommission AB is the financial advisor of DanCann Pharma in connection with the issue of units. Andersen Partners Advokatpartnerselskab is acting as legal advisor. Nordic Issuing is acting as issuing agent.
For additional information regarding the issue of units, please contact:
For more information regarding DanCann Pharma, please contact:
About DanCann Pharma
DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
This information is information that DanCann is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 28, 2020.